Medtronic MDT Income Statement
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| —— | —— | —— | —— | ||
| $36.36B+8.4% | $33.54B+3.6% | $32.36B+3.6% | $31.23B-1.4% | ||
| $12.72B+9.4% | $11.63B+3.7% | $11.22B+4.6% | $10.72B+5.7% | ||
| $23.64B+7.9% | $21.9B+3.6% | $21.15B+3.1% | $20.51B-4.8% | ||
| 65%-0.3pp | 65.3%0.0pp | 65.3%-0.3pp | 65.7%-2.3pp | ||
| $2.87B+5.2% | $2.73B-0.1% | $2.74B+1.4% | $2.7B-1.8% | ||
| $11.78B+8.6% | $10.85B+1.0% | $10.74B+3.1% | $10.42B+1.2% | ||
| $6.47B+8.6% | $5.96B+15.8% | $5.14B-6.2% | $5.49B-4.6% | ||
| 17.8%0.0pp | 17.8%+1.9pp | 15.9%-1.7pp | 17.6%-0.6pp | ||
| $714M-2.1% | $729M+1.5% | $718M+12.9% | $636M+15.0% | ||
| $383M-4.7% | $402M-2.4% | $412M-19.8% | $514M+61.6% | ||
| $6.14B+9.0% | $5.63B+16.4% | $4.84B-9.9% | $5.37B-2.8% | ||
| $1.3B+38.6% | $937M-17.4% | $1.13B-28.2% | $1.58B+246% | ||
| $4.8B+3.0% | $4.66B+26.8% | $3.68B-2.2% | $3.76B-25.4% | ||
| 13.2%-0.7pp | 13.9%+2.5pp | 11.4%-0.7pp | 12%-3.9pp | ||
| $3.74+3.3% | $3.62+31.6% | $2.75-2.5% | $2.82-24.4% | ||
| $9.43B+6.9% | $8.82B+13.2% | $7.79B-4.8% | $8.18B-3.3% | ||
| 25.9%-0.4pp | 26.3%+2.2pp | 24.1%-2.1pp | 26.2%-0.5pp | ||
| $6.47B+8.6% | $5.96B+15.8% | $5.14B-6.2% | $5.49B-4.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Medtronic's revenue?
- Medtronic (MDT) generated $36.4B in revenue over the trailing twelve months, up 8.4% year over year.
- Is Medtronic profitable?
- Medtronic reported $4.8B in net income over the trailing twelve months, a 13.0% net margin.
- What are Medtronic's profit margins?
- Gross margin is 64.9% and operating margin is 17.0%, with a 13.0% net margin.
- What is Medtronic's earnings per share?
- Medtronic's diluted EPS over the trailing twelve months is $3.74.
- Where does Medtronic's income statement data come from?
- Every line is extracted from Medtronic's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
